Table 1 Clinical and pathological characteristics
From: Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis
Parameter | N | % |
|---|---|---|
Median age (years) | 70.1 (27–90) | |
BMI, kg/m² | 27.4 (17–45) | |
Tumor (T) stage | ||
0 | 7 | |
1 | 89 | 3.3 |
2 | 71 | 42.0 |
3 | 6 | 41.0 |
4 | 23 | 2.8 |
Missing | 6 | 10.8 |
Lymph node status | ||
Negative | 113 | |
Positive | 89 | 55.9 |
Missing | 16 | 44.1 |
Histological grade | ||
1 | 21 | |
2 | 132 | 9.9 |
3 | 60 | 62.0 |
Missing | 5 | 28.2 |
Blood vessel involvement | ||
Negative | 178 | |
Positive | 10 | 94.7 |
Missing | 30 | 5.3 |
Lymph vessel involvement | ||
Negative | 114 | |
Positive | 78 | 59.4 |
Missing | 26 | 40.6 |
ER status | ||
Negative | 5 | |
Positive | 210 | 2.3 |
Missing | 3 | 97.7 |
PR status | ||
Negative | 13 | |
Positive | 202 | 6.0 |
Missing | 3 | 94.0 |
HER2 status | ||
Negative | 145 | |
Positive | 32 | 81.9 |
Missing | 41 | 18.1 |
Operative therapy | ||
No | 2 | |
Yes | 209 | 0.9 |
Missing | 7 | 99.1 |
Radiotherapy | ||
No | 100 | |
Yes | 110 | 47.6 |
Missing | 8 | 52.4 |
Chemotherapy | ||
No | 124 | |
Yes | 92 | 57.4 |
Missing | 2 | 42.6 |
